Drug Re-patenting Raises Cost by Six Times
Published By : 11 Feb 2015 | Published By : QYRESEARCH
Big Pharma companies have begun to increase the price of their most commonly used drugs after completing a process called ‘re-patenting’.
Re-patenting allows the corporations to own generic brands that have so far been sold at nominal prices, and let them sell it to consumers for exorbitant prices.
Most agencies and consumers protesting the price hike have made asthma inhalers the ruling point of the argument. Asthma is currently the most common chronic disease that afflicts Americans of all ages. Nearly 40 million U.S. citizens currently suffer from asthma. And all of them need two out of three amenities to survive: heavy disposable income, top-grade insurance, and time to sift through deals.
Protestors, for instance, are complaining about Pulmicort, steroid based inhaler. Pulmicort is a steroid inhaler which sellers have put in the market with a retail cost of US$175 within the U.S. Meanwhile, Brit pharmas continue to sell an identical drug. They sell an identical drug for US$20, and provide it free to anyone who suffers from asthma.
One of the most common and oldest known asthma drug, Albuterol, was sold at US$15 more than ten years ago before its re-patenting. The drug now typically costs between US$50 to US$100 in the U.S.
Rhinocort Aqua is another prescription drug that sold for over US$250 per month in Oakland pharmacies. The same drug costs US$7 in Europe and is also available over the counter.
The Centers of Disease Control and Prevention valued the per annum cost of asthma in the U.S. at more than US$56 billion. The estimation includes a large number of hospital visits that can be deemed unnecessary, along with avoiding at least 3,300 deaths of patients that went without medications.
Dr. Elaine Davenport, from the Oakland Breathmobile, said that asthma is completely fixable. It only requires medication and education.
The U.S. currently spends more on prescription drugs per capita than any other emerging nation.